Heparan Sulfate

SKU: orb1307056

Description

Heparan sulfate is a linear polysaccharide proteoglycan (HSPG) bound to cell surfaces and the extracellular matrix. It is widely used in research on angiogenesis, viral entry mechanisms, and growth factor signaling in both cellular and animal studies.

Research Area

Cardiovascular Research, Metabolism Research, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 9050-30-0
• MW: 593.47(monomer)
• Formula: C₁₂H₁₉NO₂₀S₃ (monomer)
• SMILES: [N].CO[C@@H]1OC(COS(O)(=O)=O)[C@H](O[C@@H]2OC([C@H](O[C@@H]3OC(COS(O)(=O)=O)[C@H](O[C@@H]4OC([C@H](OC)[C@H](O)[C@@H]4OS(O)(=O)=O)C(O)=O)[C@H](O)[C@@H]3NS(O)(=O)=O)[C@H](O)[C@@H]2O)C(O)=O)[C@H](OS(O)(=O)=O)[C@@H]1NS(O)(=O)=O
• Target: Wnt/beta-catenin,Endogenous Metabolite,FGFR
• Solubility: H2O:100 mg/mL;DMSO:Insoluble

Bioactivity

• Target IC50:
  MCF-10A cells (AR-induced mitogenesis):2 μg/mL|RBD:0.02 μg/mL
• In Vivo:
  METHODS: To assay anti-tumor activity in vivo, Heparan sulfate (0.8 mg/kg) was administered to SCID-hu mice injected with bone marrow aspirates from myeloma patients twice daily, once intraperitoneally and once subcutaneously, for four weeks. RESULTS: Treatment with Heparan sulfate significantly inhibited primary tumor growth in a human severe combined immunodeficiency (SCID-hu) myeloma model.
• In Vitro:
  METHODS: Breast cancer cells MDA-MB231 were treated with Heparan sulfate (20 µg/mL) for 24 h and detected by Fluorescence microscopy. RESULTS: Cell spreading was enhanced and the average spreading cell area approximately doubled in the presence of Heparan sulfate. Exogenous Heparan sulfate blocked cell invasion and matrix degradation.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Wnt/β-catenin, Wnt/betacatenin, Wnt, Wnt/b-catenin, βcatenin, beta-catenin, betacatenin, bcatenin, inhibit, Inhibitor, Heparan, Heparan Sulfate, EndogenousMetabolite, Endogenous Metabolite, Fibroblast growth factor receptor, FGFR, Human Endogenous Metabolite

Compound Identifiers

PubChem CID

155973927